Cultivating fresh thinking and continual adaptation is key.
Market growth can be attributed to a healthy pipeline of science and medical research institutes.
The increase in communicable diseases is elevating competition in the device arena.
Why regulatory and quality due-diligence is often overlooked.
The agency is creating a virtual center of excellence to expedite the development of combination products.
Shift the odds in your favor.
As the incidence of GI conditions grows, device companies in this segment should explore expansion in the region.
The move is expected to save as much as $1 billion.
Changing the traditional healthcare model and moving from cure to prevention will take time.
Not surprisingly, data science will reign over blockbuster drugs or devices.